Galectin-3 and Hector Battifora Mesothelial-1 immunohistochemical expression in 50 cases of thyroid neoplasms: a retrospective study done at tertiary care centre
DOI:
https://doi.org/10.18203/2349-2902.isj20241392Keywords:
Galectin-3, HBME-1, Immunohistochemistry, Thyroid carcinomaAbstract
Background: Diagnosis of thyroid carcinoma is not always straight forward on haematoxylin and eosin staining since nuclear features are inconsistent, overlapping and controversial. In regards to this, many studies on the role of immunohistochemical markers for diagnosis of malignant thyroid carcinoma are needed. In order to improve diagnostic accuracy, markers immunohistochemistry techniques have mainly emphasized on galectin-3 (Gal-3) and Hector Battifora Mesothelial-1 (HBME-1). However, results remain unsatisfactory. The aim of the present article was to establish the diagnostic accuracy of Gal-3 and HBME-1 markers, individual and in combination, in the differentiation of malignant and benign thyroid lesions.
Methods: A total of 50 thyroidectomy specimens were studied over a period of 1.5 years from September 2019 to February 2021 at Bhagwan Mahaveer Cancer Hospital Research Centre, Jaipur which included 2 benign and 48 malignant thyroid neoplasms. Histopathologic evaluation of H&E stained sections was done and immunohistochemistry (IHC) staining for Gal-3 and HBME-1 was performed for all neoplasms.
Results: For the immunohistochemistry technique, Gal-3 and HBME-1expression was significantly higher in malignant thyroid neoplasms in comparison to the benign neoplasms. Gal-3 expression for malignant neoplasms showed sensitivity of 97.92%, specificity of 50%. HBME-1 expression for malignant neoplasms showed sensitivity and specificity of 100% each. Gal-3 and HBME-1 are useful markers in differentiating benign and malignant thyroid neoplasms.
Conclusions: This study demonstrated that both immunomarkers studied are sensitive and specific for diagnosis of benign and malignant thyroid lesions. However, the need of further studies for other molecular markers must continue in order to increase the diagnostic accuracy since a proportion of cases still show false-negative and false-positive tests.
Metrics
References
Arcolia V, Journe F, Renaud F, Leteurtre E, Gabius HJ, Remmelink M, et al. Diagnostic performances of individual or combined thyroid markers. Oncol Lett. 2017;14:4183-9.
Matos LL, Giglio ABD, Matsubayashi O, Farah MDL, Giglio AD, Pinhal MADS. Expression of CK-19, galectin-3,HBME-1 in the differentiation of thyroid lesions:systemic review and meta-analysis. Diagnostic Pathol. 2012;7:97.
Davies L, Welch HG. Current Thyroid Cancer Trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140(4):317-22.
Gopal MR, Rao KJ, Sai AR. Clinico-pathological study of thyroid lesions over a period of one year in a tertiary care centre. Jemds. 2018;7(31):3513-7.
Luzon-Toro B, Fernandez RM, Villalba-Benito L, Torroglosa A, Antinolo G, Borrego S. Influencers on thyroid cancer onset: Molecular genetic basis. Genes (Basel). 2019;10(11):913.
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184-99.
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676-90.
Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. Harrison’s Principles of Internal Medicine, 16th ed.; McGraw-Hill Publishers: New York, NY, USA. 2012.
Xu D, Wang L, Long B, Ye X, Ge M, Wang K, et al. Radiofrequency ablation for postsurgical thyroid removal of differentiated thyroid carcinoma. Am J Transl. 2016;8:1876-85.
Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115:3801-7.
Alshenawy HA. Utility of immunohistochemical markers in differential diagnosis of follicular cell derived thyroid lesions. Pathol Oncol Res. 2014;20(4):819-28.
Zhou Y, Chen Z-H, Lu B-H, Jiang H-G. Diagnostic significance of Ki67, CK-19,Gal-3 and HBME-1expression for papillary thyroid microcarcinoma. Biomed Res. 2017;28(9):4002-6.
Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985;55(4):794-804.
Simpson WJ, McKinney SE, Carruthers JS, Gospodarowicz MK, Sutcliffe SB, Panzarella T. Papillary and follicular thyroid cancer Prognostic factors in 1,578 patients. Am J Med. 1987;83(3):479-88.
Rageh TM, Samaka RM, Hagag MG, Motawa EA. Relationship between focality and cervical lymph nodes metastasis in papillary thyroid carcinoma. Int Surg J. 2019;6(2):453.
Sreedevi AR, Sheela KM. Histopathological Spectrum of Non-Neoplastic and Neoplastic Lesions. J Med Clin Res. 2018;6(6):514-9.
Modi M, Daveshwar M. Study of histopathological pattern of thyroid lesions. Int J Biomed Adv Res. 2018;9(1):27-36.
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28.
Arcolia V, Journe F, Renaud F, Leteurtre E, Gabius HJ, Remmelink M, et al. Diagnostic performances of individual or combined thyroid markers. Oncol Lett. 2017;14:4183-9.
Sanuvada R, Nandyala R, Chowhan AK, Bobbidi P, Yootia M, Hulikal N, et al. Value of Cytokeratin-19,Hector Battifora Mesothelial-1 and Galectin-3 immunostaining in the diagnosis of thyroid neoplasms. J Lab Physicians. 2018;10(2).
Zhou Y, Chen Z-H, Lu B-H, Jiang H-G. Diagnostic significance of Ki67, CK-19,Gal-3 and HBME-1expression for papillary thyroid microcarcinoma. Biomed Res. 2017;28(9):4002-6.
Casey MB, Lohse CM, Lloyd RV. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003;14(1):55-60.
Downloads
Published
How to Cite
Issue
Section
